CAUGHT IN DR. WRIGHT’S NET
Until our readers begin filling the net themselves, I will occasionally share advertisements, questions, and medical claims that have crossed my own screen—and answer the questions I believe patients should be asking.
The Claim
An advertisement from Apex Regenerative says exosomes work throughout the entire body. It credits them with reducing inflammation, repairing cells, growing a healthy blood supply, regenerating damaged tissue, and starting a healing cascade across the brain, nerves, heart, lungs, liver, kidneys, joints, muscles, and skin.
WHAT THE ADVERTISEMENT SAYS
- “Reduce inflammation” — “Calm the body”
- “Protect & repair cells” — “Help injured tissue recover”
- “Grow new, healthy blood supply” — “Bring oxygen & nutrients”
- “Regenerate damaged tissue” — including “nerves, joints, bone, muscle and more”
- “Start a healing cascade” — “Restore healthy function”
The advertisement concludes that exosomes can support healing in “every major system” and depicts the brain, nerves, heart, lungs, liver, kidneys, joints, muscles, and skin.
The missing information: Which exact exosome product produced each claimed benefit, in what dose and by what route, in which controlled human trials, and with what safety findings?
That leads to a fair question:
If exosomes are part of real science, does that mean an exosome treatment being sold today has been proven to heal the whole body?
The Short Answer
No.
Exosomes and other extracellular vesicles are real biological particles. They carry proteins, lipids, and genetic material between cells, and researchers are investigating them in inflammation, wound healing, tissue repair, drug delivery, cancer, neurologic disease, and many other fields.
But biological plausibility is not the same as clinical proof.
The existence of laboratory studies showing that a particular extracellular-vesicle preparation affects a particular cell, animal, or disease model does not prove that a commercial product will safely regenerate multiple organ systems in people.
What Are Exosomes?
Cells release tiny membrane-bound packages known as extracellular vesicles. Exosomes are one category within that broader family. These vesicles can carry signaling molecules from one cell to another and influence immune activity, blood-vessel growth, tissue remodeling, and other biological processes.
That communication system makes extracellular vesicles scientifically compelling. It also makes the word exosome sound like a single uniform medicine.
It is not.
An extracellular-vesicle product can differ according to:
- The cells from which it was produced
- The health and characteristics of the donor
- The conditions under which the cells were grown
- How the vesicles were isolated and purified
- The concentration, dose, and route of administration
- How the preparation was stored
- Its sterility, potency, identity, and contaminants
- Whether the final product actually contains what its label claims
Results from one carefully characterized research preparation cannot automatically be transferred to every product marketed as “exosomes.”
What the Research Actually Shows
Laboratory and animal studies provide evidence that some extracellular-vesicle preparations can alter inflammatory signaling, affect macrophage behavior, encourage angiogenesis, and support tissue repair in specific experimental settings.
Small early human studies and clinical trials are also exploring extracellular vesicles in selected conditions. That is legitimate and important research.
But the evidence is fragmented. Preparations, cell sources, purification methods, doses, routes, and outcomes vary substantially. Many studies remain preclinical; many human studies are small, early-phase, uncontrolled, or focused on narrow indications.
A study of umbilical-cord-derived vesicles in one disease model does not demonstrate simultaneous benefit to the brain, heart, lungs, kidneys, joints, nerves, muscles, liver, and skin. Nor does a paper about a biological mechanism validate a clinic’s particular vial.
Where the Advertisement Makes Its Leap
The advertisement takes several effects that extracellular vesicles may produce under some experimental conditions and presents them as though a treatment can reliably direct those effects throughout the human body.
That is the unsupported leap.
For a whole-body therapeutic claim to be convincing, we would need to know:
- The exact product being administered
- Its source, manufacturing method, and quality controls
- The dose and route of administration
- The specific condition being treated
- The clinical outcomes measured
- The number and characteristics of the patients studied
- The comparator or control group
- The duration of follow-up
- The adverse-event profile
- Whether independent investigators reproduced the result
A list of papers about different vesicles, tissues, and experimental models does not substitute for trials of the product being sold.
What Does the FDA Say?
The FDA states that exosome products intended to treat disease are regulated as drugs and biological products and require review before marketing. Its public safety notice says there are no FDA-approved exosome products and describes reports of serious adverse events involving unapproved products marketed as containing exosomes.
The agency advises patients considering an exosome treatment to ask whether it has been reviewed by the FDA. When a product is being studied under an Investigational New Drug application, patients can ask for the IND number and information about the responsible Institutional Review Board.
“Experimental” should mean studied under meaningful oversight—not simply sold with a consent form and a scientific-sounding explanation.
Questions to Ask Before Paying for an Exosome Treatment
- What is the exact product name and manufacturer?
- What human trial studied this exact product for my exact condition?
- Is there an FDA-approved indication or an active IND?
- What confirms identity, sterility, purity, potency, and dose?
- What adverse events have occurred?
- Who is responsible if I am harmed?
- Am I being asked to delay or replace an established treatment?
If the answers return repeatedly to animal studies, testimonials, before-and-after photographs, or research performed on a different preparation, the evidence has not caught up with the sale.
The Founder’s Verdict
Stringer Scale: Promising science; unproven commercial catch.
Exosomes are not imaginary, and extracellular-vesicle research should not be dismissed. They may eventually become useful therapeutic tools.
But this advertisement compresses an enormous, heterogeneous research field into a promise of systemic healing. The evidence does not currently establish that a commercial exosome product can safely reduce inflammation, repair cells, grow blood vessels, regenerate damaged tissue, and restore function across every major human organ system.
The science is real. The whole-body promise is not yet proven.
— Milton Wright, DO, FACOFP
Founding Director
Founders Institute of Medicine & Education
Sources: FDA Public Safety Notification on Exosome Products | Clinical Applications of Exosomes: A Critical Review (2024) | Systematic review of published clinical extracellular-vesicle studies | ClinicalTrials.gov: extracellular-vesicle infusion study
Educational information only. Not medical advice. This review evaluates public claims and does not determine the composition, sterility, or safety of any individual product.